Provost, G.
Lavoie, F. B.
Larbi, A.
Ng, TP.
Ying, C. Tan Tze
Chua, M.
Fulop, T.
Cohen, A. A.
Funding for this research was provided by:
National Medical Research Council (NMRC/1108/2007, NMRC/1108/2007, NMRC/1108/2007, NMRC/1108/2007)
Canadian Institutes of Health Research (106634, 106634)
Fonds de Recherche du Québec - Santé (2020/AUDC/270433, 2020/AUDC/270433, 2020/AUDC/270433)
Biomedical Research Council (BMRC/08/1/21/19/567, BMRC/08/1/21/19/567, BMRC/08/1/21/19/567)
National Science and Engineering Research Council (RGPIN-2018-06096)
Article History
Received: 27 February 2022
Accepted: 13 July 2022
First Online: 4 August 2022
Declarations
:
: Ethics approval was obtained from National University of Singapore IRB(Ref:04–140). All participants gave written informed consent to participate in the study. Ethics approval for secondary analysis of the data was obtained from the University of Sherbrooke ethic board (Ref number: 2019–2657).
: Not applicable.
: AAC is founder and CEO at Oken Health.